# Celltrio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celltrio

- Industry: Biotechnology
- Headquarters: Fremont, US
- Website: www.celltrio.com
- Total disclosed funding: $3M
- Latest round: Series A (Jun 17, 2025)
- Investors on record: 1

## About

Celltrio is a US-based company that provides advanced automation solutions for cell maintenance and culture, enhancing laboratory efficiency through cutting-edge technology. Their flagship product, RoboCell™, automates complex workflows in cell line management.Founded in 2018 and headquartered in Fremont, US, Celltrio specializes in automating cell maintenance and culture processes. The company has secured funding totaling USD 15.00 mn in a recent venture round led by Premier Partners on June 17, 2025. It operates independently without known subsidiaries or parent companies. The founder's previous entrepreneurial history is currently not available.Celltrio specializes in providing advanced automation solutions for cell maintenance and culture, with a core offering centered around their RoboCell™ system. This system operates continuously to streamline processes including cell passage, differentiation, transformation, and biobanking, ensuring high-quality management of a diverse range of cell lines, including primary, immortalized, and induced pluripotent stem cells (iPSCs). The technology incorporates a user-friendly visual interface that allows clients to define, schedule, and monitor complex workflows in real time, providing crucial metrics on environmental conditions and inventory status. Celltrio's customer base includes research institutions, biotechnology companies, and pharmaceutical organizations, predominantly located in North America, Europe, and Asia. The company's solutions address critical challenges in laboratory efficiency and data traceability, catering to clients who require rigorous documentation and performance tracking for their cell line development and assay processes.Celltrio's revenue model is structured around the sale and leasing of their RoboCell™ automation systems, complemented by subscription services for software updates and maintenance. Transactions typically occur directly between Celltrio and its clients, with agreements often encompassing long-term partnerships that include training, support, and consumable supplies necessary for cell culture operations. The pricing structure reflects the extensive capabilities of their flagship RoboCell™ system, which integrates multiple functions into a single platform, making it a pivotal investment for laboratories seeking to enhance their operational efficiency. Ongoing revenue is also generated through the provision of consumables and accessories essential for cell culture maintenance, fostering repeat business from established clients. This transactional approach ensures a stable revenue stream as clients seek to optimize their research processes and expand their laboratory capacities.In June 2025, Celltrio raised USD 15 mn in venture funding led by Premier Partners. The company plans to utilize this funding to accelerate its geographical expansion and enhance manufacturing capabilities. This strategy includes launching new products designed to optimize laboratory automation and targeting specific markets in Europe and Asia for expansion.

## Funding rounds

- Series A, Jun 17, 2025, $3M — Premier Partners

## Investors

- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series A